• Asiya Parvin Allaudeen Anna University BIT Campus
  • C. Manjula Anna University BIT Campus
  • N. Jothi Anna University BIT Campus
  • C. Vignesh Kumar Anna University BIT Campus
  • B. Indramani Anna University BIT Campus
  • V. Shunmuga Priya Anna University BIT Campus
  • E. Bhakkiyalakshmi SRM University
  • K. M. Ramkumar SRM University
  • P. Rajaguru Department of Biotechnology, Anna University BIT Campus, Tiruchirappalli, Tamil Nadu, India


Breast cancer, eIF3A, MCF-7, RNA interference, miR-30


Objective: The eukaryotic translational initiation factor 3A (eIF3A) is reported to be over expressed in most breast cancer cells. In the present study, our aim is to suppress the over expression of eIF3A in human breast cancer MCF-7 cell line using gene silencing technique (RNA interference (RNAi)).

Methods: The artificial microRNA (amiRNA) targeting eIF3A gene was constructed by incorporating short interference RNA (siRNA) sequences against eIF3A gene into endogenous microRNA30 (miR-30) and cloned into pcDNA3.1 vector. The amiRNA containing plasmid was then transfected into MCF-7 cell line and the expression of eIF3A was examined by RT-PCR. The cytotoxicity of plasmid with amiRNA targeting eIF3A on MCF–7 cells was evaluated by MTT assay.

Results: The amiRNA construct significantly inhibited eIF3A gene expression and reduce the cell viability of MCF-7 cell line.

Conclusion: The usage of modified endogenous amiRNA in vector based expression system with significant gene silencing efficiency suggests that RNAi based gene silencing method can be considered as one of the effective means to control cancer.



Download data is not yet available.


DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics. CA-Cancer J Clin 2011;61:408-18.

Morgan G, Ward R, Barton M. The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clin Oncol 2004;16:549-60.

Gibbs J. Mechanism-based target identification and drug discovery in cancer research. Science 2000;287:1969.

Dong Z, Zhang J-T. Initiation factor eIF3 and regulation of mRNA translation, cell growth, and cancer. Crit Rev Oncol Hematol 2006;59:169-80.

Hershey JWB. Regulation of protein synthesis and the role of eIF3 in cancer. Braz J Med Biol Res 2010;43:920-30.

Dong Z, Liu LH, Han B, Pincheira R, Zhang J-T. Role of eIF3 p170 in controlling synthesis of ribonucleotide reductase M2 and cell growth. Oncogene 2004;23:3790-801.

Donze O, Jagus R, Koromilas AE, Hershey JW. Abrogation of translation initiation factor eIF-2 phosphorylation causes malignant transformation of NIH 3T3 cells. EMBO J 1995;14:3828.

Hinnebusch AG. eIF3: a versatile scaffold for translation initiation complexes. Trends Biochem Sci 2006;31:553-62.

Rothe M, Ko Y, Albers P, Wernert N. Eukaryotic initiation factor 3 p110 mRNA is overexpressed in testicular seminomas. Am J Pathol 2000;157:1597-604.

Doldan A, Chandramouli A, Shanas R, Bhattacharyya A. Loss of the eukaryotic initiation factor 3f in melanoma. Mol Carcinog 2008;47:806-13.

Kozak M, Evans M, Gardner PD, Flores I. Structural features in eukaryotic mRNAs that mod. Biol Chem 1991;266:19867-70.

Fraser CS, Lee JY, Mayeur GL, Bushell M. The j-subunit of human translation initiation factor eIF3 is required for the stable binding of eIF3 and its subcomplexes to 40 S ribosomal subunits in vitro. J Biol Chem 2004;279:8946-56.

Miyakoshi T, Miyajima K, Takekoshi S, Osamura RY. The influence of endocrine disrupting chemicals on the proliferation of ERα knockdown-human breast cancer cell line MCF-7; new attempts by RNAi technology. Acta Histochem Cytochem 2009;42:23-8.

Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21-and 22-nucleotide RNAs. Gene Dev 2001;15:188-200.

Ambros V. microRNAs: tiny regulators with great potential. Cell 2001;107:823-6.

Bachmann F, Bänziger R, Burger MM. Cloning of a novel protein over expressed in human mammary carcinoma. Cancer Res 1997;57:988-94.

Dellas A, Torhorst J, Bachmann F, Bänziger R. Expression of p150 in cervical neoplasia and its potential value in predicting survival. Cancer 1998;83:1376-83.

Saletta F, Rahmanto YS, Richardson DR. The translational regulator eIF3a: the tricky eIF3 subunit. Biochim Biophys Acta 2010;1806:275-86.

Chen G, Burger MM. p150 over expression in gastric carcinoma: the association with p53, apoptosis and cell proliferation. Int J Cancer 2004;112:393-8.

Shen X, Yang Y, Liu W, Sun M. Identification of the p28 subunit of eukaryotic initiation factor 3 (eIF3k) as a new interaction partner of cyclin D3. FEBS Lett 2004;573:139-46.

Shan Z, Lin Q, Deng C, Li X. An efficient method to enhance gene silencing by using precursor micro RNA designed small hairpin RNAs. Mol Biol Rep 2009;36:1483-9.

Shan ZX, Lin QX, Deng CY, Zhou ZL. Comparison of approaches for efficient gene silencing induced by microRNA-based short hairpin RNA and indicator gene expression. Mol Biol Rep 2010;37:1831-9.

Zhou H, Xia XG, Xu Z. An RNA polymerase II construct synthesizes short-hairpin RNA with a quantitative indicator and mediates highly efficient RNAi. Nucleic Acids Res 2005;33:e62-e68.

Silvera D, Formenti SC, Schneider RJ. Translational control in cancer. Nat Rev Cancer 2010;10:254-66.



How to Cite

Allaudeen, A. P., C. Manjula, N. Jothi, C. V. Kumar, B. Indramani, V. S. Priya, E. Bhakkiyalakshmi, K. M. Ramkumar, and P. Rajaguru. “RNAI MEDIATED GENE SILENCING OF EIF3A: A POSSIBLE SOLUTION TO CONTROL BREAST CANCER”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 7, no. 11, Nov. 2015, pp. 289-93, https://journals.innovareacademics.in/index.php/ijpps/article/view/8357.



Original Article(s)

Most read articles by the same author(s)